12,000 Shares in Medtronic PLC $MDT Acquired by SBI Okasan Asset Management Co.Ltd.

SBI Okasan Asset Management Co.Ltd. acquired a new position in Medtronic PLC (NYSE:MDT) in the fourth quarter, Holdings Channel reports. The fund acquired 12,000 shares of the medical technology company’s stock, valued at approximately $1,154,000.

Several other large investors have also recently made changes to their positions in the stock. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Medtronic by 4.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 176,792 shares of the medical technology company’s stock valued at $16,983,000 after purchasing an additional 7,984 shares during the period. Ilmarinen Mutual Pension Insurance Co acquired a new position in shares of Medtronic in the fourth quarter valued at about $5,283,000. Huntington National Bank increased its holdings in shares of Medtronic by 1.6% in the fourth quarter. Huntington National Bank now owns 174,510 shares of the medical technology company’s stock valued at $16,763,000 after purchasing an additional 2,698 shares during the period. Kingsview Wealth Management LLC increased its holdings in shares of Medtronic by 14.8% in the fourth quarter. Kingsview Wealth Management LLC now owns 19,467 shares of the medical technology company’s stock valued at $1,870,000 after purchasing an additional 2,506 shares during the period. Finally, Community Bank & Trust Waco Texas increased its holdings in shares of Medtronic by 2.9% in the fourth quarter. Community Bank & Trust Waco Texas now owns 19,210 shares of the medical technology company’s stock valued at $1,845,000 after purchasing an additional 547 shares during the period. 82.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Robert W. Baird increased their price objective on Medtronic from $92.00 to $93.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. Truist Financial cut their price objective on Medtronic from $103.00 to $95.00 and set a “hold” rating on the stock in a report on Wednesday, April 15th. Citigroup cut their price objective on Medtronic from $117.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. The Goldman Sachs Group set a $84.00 price target on Medtronic and gave the stock a “neutral” rating in a research report on Thursday, May 21st. Finally, Weiss Ratings downgraded Medtronic from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, May 21st. Fifteen analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to MarketBeat, Medtronic has an average rating of “Moderate Buy” and a consensus price target of $106.45.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s Evolut TAVR platform was highlighted for superior clinical outcomes, which could support the company’s competitive position in a market expected to grow from $7.0 billion in 2025 to $13.8 billion by 2035. Medtronic’s Evolut displays superior clinical outcomes
• Positive Sentiment: Some commentary suggests Medtronic may be trading closer to fair value after its recent pullback, with M&A activity, FDA clearances, and product strength providing longer-term upside potential. Medtronic’s Fair Value Falls Between Caution And Optimism
• Neutral Sentiment: Analysts continue to frame Medtronic as a mixed story into earnings, with some seeing the stock as fairly valued after its decline and others watching whether acquisitions and new product approvals can offset slower growth. Can Medtronic (MDT) Close the Growth Gap With Its Bigger MedTech Rivals?
• Neutral Sentiment: Medtronic is scheduled to report earnings on June 3, and coverage ahead of the release has focused on expectations for a earnings decline, which is keeping sentiment cautious. Analysts Estimate Medtronic (MDT) to Report a Decline in Earnings: What to Look Out for
• Negative Sentiment: Investor sentiment remains pressured ahead of earnings, with the stock recently down over short time frames and a voluntary Class II software recall adding another near-term headwind. Medtronic (MDT) Valuation Check As Earnings Approach And M&A FDA Moves And Recall Shape Sentiment
• Negative Sentiment: Recent trading showed Medtronic slipping despite a broader market advance, reinforcing the view that investors are rotating out of the name until the earnings update provides more clarity. Medtronic (MDT) Stock Drops Despite Market Gains: Important Facts to Note

Medtronic Stock Performance

Shares of MDT stock opened at $75.56 on Friday. The company has a market capitalization of $97.01 billion, a P/E ratio of 21.05, a P/E/G ratio of 1.81 and a beta of 0.62. The business’s 50 day moving average is $82.63 and its two-hundred day moving average is $92.78. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12-month low of $74.40 and a 12-month high of $106.33.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were given a dividend of $0.71 per share. The ex-dividend date was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.8%. Medtronic’s dividend payout ratio is currently 79.11%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).